Microsoft Excel LibreOffice Calc

Merck & Co. Inc. (NYSE:MRK)

Paying users zone. Data is hidden behind: .

  • Get 1-month access to Merck & Co. Inc. for $19.99, or

  • get full access to the entire website for at least 3 months from $49.99.

We accept:

Visa Mastercard American Express Maestro Discover JCB PayPal Apple Pay Google Pay
Verified by Visa MasterCard SecureCode American Express SafeKey
Unlock

This is a one-time payment. There is no automatic renewal.

Cash Flow Statement
Quarterly Data

Beginner level

The cash flow statement provides information about a company’s cash receipts and cash payments during an accounting period, showing how these cash flows link the ending cash balance to the beginning balance shown on the company’s balance sheet.

The cash flow statement consists of three parts: cash flows provided by (used in) operating activities, cash flows provided by (used in) investing activities, and cash flows provided by (used in) financing activities.

Merck & Co. Inc., consolidated cash flow statement (quarterly data)

US$ in millions

Microsoft Excel LibreOffice Calc
3 months ended Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jun 30, 2018 Mar 31, 2018 Dec 31, 2017 Sep 30, 2017 Jun 30, 2017 Mar 31, 2017 Dec 31, 2016 Sep 30, 2016 Jun 30, 2016 Mar 31, 2016 Dec 31, 2015 Sep 30, 2015 Jun 30, 2015 Mar 31, 2015
Net income (loss)
Depreciation and amortization
Intangible asset impairment charges
Charge for acquisition of Peloton Therapeutics, Inc.
Charge for future payments related to collaboration license options
Charge for collaboration termination
Provisional charge for one-time transition tax related to the enactment of U.S. tax legislation
Charge related to the settlement of worldwide Keytruda patent litigation
Foreign currency devaluation related to Venezuela
Net charge related to the settlement of Vioxx shareholder class action litigation
Deferred income taxes
Share-based compensation
Other
Net changes in assets and liabilities
Adjustments to reconcile net income (loss) to net cash provided by operating activities
Net cash provided by operating activities
Capital expenditures
Purchases of securities and other investments
Proceeds from sales of securities and other investments
Acquisition of ArQule, Inc., net of cash acquired
Acquisition of Antelliq Corporation, net of cash acquired
Acquisition of Peloton Therapeutics, Inc., net of cash acquired
Other acquisitions, net of cash acquired
Dispositions of businesses, net of cash divested
Other
Net cash (used in) provided by investing activities
Net change in short-term borrowings
Payments on debt
Proceeds from issuance of debt
Purchases of treasury stock
Dividends paid to stockholders
Proceeds from exercise of stock options
Other
Net cash provided by (used in) financing activities
Effect of exchange rate changes on cash, cash equivalents and restricted cash
Net increase (decrease) in cash, cash equivalents and restricted cash

Based on: 10-Q (filing date: 2020-05-06), 10-K (filing date: 2020-02-26), 10-Q (filing date: 2019-11-05), 10-Q (filing date: 2019-08-06), 10-Q (filing date: 2019-05-08), 10-K (filing date: 2019-02-27), 10-Q (filing date: 2018-11-06), 10-Q (filing date: 2018-08-07), 10-Q (filing date: 2018-05-08), 10-K (filing date: 2018-02-27), 10-Q (filing date: 2017-11-07), 10-Q (filing date: 2017-08-08), 10-Q (filing date: 2017-05-09), 10-K (filing date: 2017-02-28), 10-Q (filing date: 2016-11-07), 10-Q (filing date: 2016-08-08), 10-Q (filing date: 2016-05-09), 10-K (filing date: 2016-02-26), 10-Q (filing date: 2015-11-05), 10-Q (filing date: 2015-08-06), 10-Q (filing date: 2015-05-07).

Cash flow statement item Description The company
Net cash provided by operating activities Amount of cash inflow (outflow) from operating activities, excluding discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities. Merck & Co. Inc.’s net cash provided by operating activities increased from Q3 2019 to Q4 2019 but then decreased significantly from Q4 2019 to Q1 2020.
Net cash (used in) provided by investing activities Amount of cash inflow (outflow) of investing activities, excluding discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets. Merck & Co. Inc.’s net cash (used in) provided by investing activities decreased from Q3 2019 to Q4 2019 and from Q4 2019 to Q1 2020.
Net cash provided by (used in) financing activities Amount of cash inflow (outflow) of financing activities, excluding discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit. Merck & Co. Inc.’s net cash provided by (used in) financing activities increased from Q3 2019 to Q4 2019 and from Q4 2019 to Q1 2020.